Introduction
============

Since the onset of synthetic biology in the early 1990s to the explosion of genomics data in the early 2000s, a new discipline has emerged. The exact definition of synthetic biology is still an intriguing question to many. One of the first uses of this concept was with the discovery of restriction enzymes with the Nobel Prize in Physiology and Medicine in 1978 ([@B58]). The engineering of microorganisms for the production of compounds has been followed for a long time. Now, based on the advent of genome-based methods synthetic biology is a rigorous engineering discipline to create, control and program cellular behavior. In this understanding the end goal is to ultimately be able to engineer a system/organism to perform how we want it to perform ([@B6]). This concept has also been extensively used in the discovery and understanding of natural product (NP) research in different microorganisms. Microorganisms are a treasure trove of NPs and the potential has just been realized with the beginning of the genomics era ([@B4]). Concerning the synthetic biology aspects of NP research much has also been done in the model organism *Saccharomyces cerevisiae* because of its vast toolkit in making different genomic manipulations ([@B54]). But as will be discussed in the following review, filamentous fungi also hold the potential as organisms that can be used in the field of synthetic biology to essentially control the production of NPs. Whether looking at it from the perspective of novel products or optimizing production conditions of known bioactive molecules, fungi have proven their own potential as work horses in the field of NP research. Different aspects will be discussed in this review from the manipulation of different regulatory/enzyme elements to the use of fungal NP gene clusters or the fungus itself in heterologous expression.

Manipulation of Natural Product Regulatory Elements
===================================================

The dawn of genome sequencing has unveiled the capacity microorganisms hold in order to create different NPs. This is also true for filamentous fungi, where in some species close to 80 different gene clusters have been predicted ([@B25]). Since most of these potential gene clusters are not expressed under standard laboratory conditions, different methods have been used in order to activate these silent/cryptic gene clusters ([@B4]). Most of the examples entail manipulation of the different regulatory elements in the gene cluster or global regulators (LaeA or VelA; [@B66]; [@B51]). Additionally, the manipulation of different signaling pathways, such as protein kinases (PK) and protein phosphatases (PP), can strongly influence the expression of NP gene clusters (Figure [1A](#F1){ref-type="fig"} [@B61]).

![**Synthetic biology strategies for natural product production in filamentous fungi.** Different strategies that could be used to activate computationally identified gene clusters: **(A)** Manipulation of different elements of signal transduction pathways leading to novel or different regulation of NPs. The activation (by phosphorylation) of transcription factors (TF), global or NP gene cluster specific, can be achieved by specific stimuli (signal), engineering of protein kinases (PK), or deletion of signal repressors such as protein phosphatases (PP); **(B)** Heterologous expression of known or unknown NP gene clusters in an amenable host to achieve production of novel/bioactive NPs. This includes the assembly of a plasmid containing the necessary/putative genes involved and then transformation and heterologous expression to achieve production; **(C)** Domain swapping of different parts of multidomain biosynthetic enzymes such as PKSs. Different aspects such as the swapping of the C or N terminal domains have been accomplished for production of novel NPs.](fmicb-06-00775-g0001){#F1}

One of the first examples entailed overexpressing a gene cluster specific transcription factor to activate the production of a novel compound. This was done in the model organism *Aspergillus nidulans* and resulted in the production of the novel aspyridones ([@B3]). This technique is of particular interest because many different promoters can be utilized from constitutive to inducible expression. Examples can range from constitutive promoters; such as the *gpdA* (glyceraldehyde-3-phosphate dehydrogenase; [@B44]) or the *otef* synthetic promoter modified from the original *tef* promoter ([@B56]) to inducible promoters such as the *alcA* (alcohol dehydrogenase I) promoter, the *pXyl* xylose inducible promoter ([@B69]) or the tetracycline-inducible promoter system ([@B20]; [@B35]). These are just to name a few, but new promoters are constantly being adapted and studied to optimize different aspects of regulation. Additionally, other approaches for the activation of silent clusters can also result from the cocultivation of different microorganisms. Two examples of cocultivations of *Streptomyces rapamycinicus* with *A. nidulans* and *A. fumigatus*, where in both cases silent NP clusters were activated and new NP produced ([@B52]; [@B30]). From the synthetic biology perspective this interaction has also been studied and found that chromatin modifications play a key role in this interaction. In a groundbreaking study by [@B40] it was found that the bacterium, *S. rapamycinicus*, actually activates a histone acetyltransferase (HAT) in the fungus resulting in the activation of this silent gene cluster. This HAT, GcnE, part of the Saga/Ada complex was also found to play a role in the regulation of different NPs and in a further study it was shown that when specific amino acids on the histone tail of H3 were replaced mimicking acetylation or non-acetylation it affected the production of different NPs ([@B39]). This work shows the potential of manipulating the chromatin landscape to activate/repress different aspects of secondary metabolism. Other examples using chromatin modifications for the regulation of different NPs have been previously reviewed ([@B36]).

Besides the activation of different NPs, there is also a growing field encompassing the compartmentalization/localization of NPs in filamentous fungi. Early studies focused on the peroxisome and penicillin biosynthesis. Peroxisomes are specialized organelles in eukaryotes involved in a variety of functions from primary, β-oxidation of fatty acids, to secondary metabolism, where they play a role in penicillin biosynthesis ([@B2]). Interestingly, the first two steps of penicillin biosynthesis take place in the cytosol, but the last step occurs within the peroxisome ([@B57]). Different studies have shown synthetic biology techniques manipulating the peroxisome number ([@B41]) to localizing other genes from the penicillin pathway into the peroxisome ([@B22]), where both resulted in an increase in penicillin production. Besides penicillin, other metabolites have also been shown to be localized to the peroxisomes such as siderophores in *A. fumigatus* and aflatoxin biosynthesis in *A. flavus* ([@B45]; [@B18]). The compartmentalization of NP products has been extensively reviewed by other groups ([@B29]), but the potential to use this knowledge and apply it to synthetic biology is endless. Keeping the precursors and enzymes in tightly controlled compartments is a dream that many scientists envision and to better understand this would help in increasing product yields and may be useful in the discovery of novel NPs.

Two other examples that epitomize the use of different regulatory elements for the production of NPs in filamentous fungi are from two different genera, *Aspergillus* and *Fusarium*. In both examples they established a novel fungal expression system using a promoter and an activator from an NP gene cluster. The first example with the equisetin biosynthetic pathway from *Fusarium heterosporum* utilized the native promoter from the polyketide synthase (PKS) gene and overexpression of the transcription factor in the native host. The native promoter was then used with an unknown PKS that was found to produce the antituberculosis agent pyrrolocin ([@B26]). This method is very beneficial when using the host *F. heterosporum*; while the study of [@B17] is a good example using different fungal hosts. In this study the authors assembled a ready-to-use plasmid where simple insertion of genes of interest can be used under the control of the constitutive promoter and governing regulatory gene that is also present in the plasmid. The system is very similar to the study from *F. heterosporum*, but this study uses *Aspergillus terreus* and the terrein NP cluster. This cluster in the native host produces a significant amount of terrein (\>1.1 g/L), thus creating a fungal expression system with the native promoter and transcriptional activator is advantageous ([@B17]). These two examples, both using regulatory elements to help increase/express NPs, whether novel or for industrial purposes, are good examples of coupling production with regulation in a heterologous host.

Fungal Heterologous Expression Systems
======================================

The use of heterologous expression systems is a major topic in the study of fungal synthetic biology, because it not only allows one to study fungal enzymes/pathways in different hosts, but also shows the capacity of fungi to be the heterologous host. This topic of fungi as heterologous expression systems has been reviewed quite extensively in earlier review articles ([@B53]; [@B33]) and a more recent article from the Mortensen lab ([@B1]), but in this work, we will highlight a few major advances in heterologous expression regarding synthetic biology. From one of the first attempts of heterologous expression in 1990 of expressing the penicillin biosynthetic gene cluster ([@B55]) many other studies have shown that fungal biosynthetic enzymes can be a valuable tool for the production of NPs. But the question remains as to which host will be used. There are many studies showing fungal NP enzymes in various hosts from different prokaryotes, such as *Escherichia coli*, to different eukaryotes, such as *S. cerevisiae* ([@B28]) to even higher eukaryotes like the tobacco plant *Nicotiana tabacum* ([@B65]). One of the most promising studies to date a non filamentous fungal host was done in the yeast *Pichia pastoris*, which is also known for its high production of heterologous proteins ([@B7]). In this particular study the *A. terreus* 6-methylsalicylic acid (6-MSA) synthase, which is a PKS, was coexpressed with the *A. nidulans* phosphopantetheinyl transferase (PPTase) gene and resulted in yields of 6-MSA as high as 2.2 g/L ([@B16]). This was the highest yield reported thus far from all the studies listed above, which also expressed the PKS for 6-MSA. But a lot of effort has also been put in optimizing *S. cerevisiae* for the production of fungal NPs. A recent review covers the entire field along with the use of fungal enzymes in *S. cerevisiae* ([@B54]). One particularly interesting example in *S. cerevisiae* was with the pathway for rubrofusarin, where four different enzymes from two different filamentous fungi were expressed. Rubrofusarin biosynthesis is of interest because the intermediates are branch points of pigmented compounds in the spores of many different fungi ([@B48]).

In most cases when heterologously expressing fungal NP enzymes/pathways using a host that is from the same species results in a stronger likelihood of a positive result. Moreover, using a host that already possesses the ability of producing NPs will also improve the chances for success. Many different filamentous fungi have been used and shown to be ample hosts for heterologous expression of NPs. The most prominent thus far being *Aspergillus oryzae* ([@B50], [@B49]; [@B21]) and *Aspergillus niger* which is used as an industrial production strain for the synthesis of different organic acids, such as citric acid ([@B42]), along with NP production ([@B46]).

Heterologous expression can also be used in the discovery of novel NPs. Examples of this include coexpression of different genes to get novel prenylated cyclic dipeptides ([@B63]) to the combination of different ergot alkaloid biosynthetic genes to get novel products ([@B47]). Other examples have been from other fungi where genetic manipulation is still not established but their genomic sequences are accessible. This being the case of the expression of a NP gene cluster from dermatophytes into the model organism *A. nidulans* and different PKS genes from *Talaromyces stipitatus* in *A. oryzae*, both resulting in new products ([@B67]; [@B19]). These are just a few different ways in which heterologous expression can be useful especially in eukaryotes.

In the genomic era with all the different NP gene clusters uncovered there are a couple of important things to consider when utilizing heterologous expression. One is the actual detection of the product once transformed into the heterologous host. This could be one downfall when using a related species of filamentous fungi, because of their complex NP metabolome. Thus, making *S. cerevisiae* a frequently chosen host in the hunt for novel products, because of its lack of NP production. But there are a number of drawbacks resulting from just the fact that *S. cerevisiae* is not a natural host for NP production, e.g., the lack of PPTase genes or, possibly, the lack of precursors for NPs. But one of the best examples of this was done in *A. nidulans* where a very efficient heterologous expression host was developed. Essentially, many of the major NP clusters that could be highly detected were deleted, leaving the wild-type strain to have an almost "clean" background, which allowed for the easy detection of heterologously expressed clusters ([@B9]). Additionally, one must also plan on how to assemble the genes/pathway before transformation into a heterologous host. This is in particular necessary when the cluster of desire lacks a pathway-specific transcription factor and thus overexpression of a transcription factor gene and thus expression of all cluster genes cannot be easily achieved.

Some classical ways can be done by simple PCR ([@B38]), but in one recent example a novel strategy for the bioprospecting of NPs was exemplified. In this example a plasmid consisting of genes encoding for the biosynthesis of penicillin were assembled by TAR cloning in *S. cerevisiae* and then transformed into an *A. nidulans* strain that is a non-producer of penicillin. Interestingly, in this case only one plasmid was needed containing every gene necessary for the production and once incorporated was also designed to be under the control of a single inducible promoter. This in turn is important because of the regulation of an entire cluster using one promoter that once transcribed would be present as a polycistronic mRNA. In addition when designing the original plasmid, between each individual gene, 2A viral peptides were used to separate them, which when translated by the ribosome cleaved each individual protein resulting in the production of penicillin ([@B59]). This strategy incorporates many different techniques into the field of filamentous fungi synthetic biology from a novel expression system to the use of heterologous expression (Figure [1B](#F1){ref-type="fig"}). This technique exemplifies the reach we can achieve with synthetic biology and the control of NP production.

Engineering of Fungal Biosynthetic Enzymes
==========================================

Another aspect of synthetic biology entails the engineering of different biosynthetic enzymes, with a particular emphasis on the major players in NP biosynthesis, which are the multidomain PKSs and non-ribosomal peptide synthetases (NRPSs). Up until now, much work has been done to understand the mechanisms of these enzymes in both fungi and bacteria ([@B13]; [@B62]; [@B24]). A lot of work has also been performed in understanding these important biosynthetic enzymes in eukaryotes especially in filamentous fungi. Interestingly, in these organisms, type I-like PKSs are also present, but they work in an iterative way, repeating specific biosynthetic steps cyclically. Until now, we still cannot understand how these processes are regulated, and what are the "criteria" that drive the exact numbering of the different steps. This makes it almost impossible to make a computational prediction of the polyketide product, which can be sometimes only deduced based on the similarities with previously described enzymes ([@B23]; [@B8]). Thus, much of the work up until now has been on achieving a better understanding of just how these particular enzymes function and with this understanding a better rationale can be used to engineer them. But of course these first studies have shown much potential for the future and use of these biosynthetic machines for the creation of novel compounds. Additionally, different and novel domains have been discovered in non-reducing PKS (NR-PKS) such as the starter unit acyl transacylase (SAT; [@B10]) to the product template domain (PT; [@B12]). Also, obtaining a crystal structure of these proteins is very difficult because of their insolubility, their size and apparent flexibility, but in the case with the PT domain from the NR-PKS from aflatoxin biosynthesis it was shown and gave even further insight into the core structure of the protein ([@B11]). These studies were ground breaking for further studies on NR-PKS, where further manipulation could be completed by domain swapping of C or N terminal domains with different NR-PKS ([@B60]; [@B32]; [@B37]). With the domain swapping of the different NR-PKSs it really showed that a need for an "intimate" knowledge of the workings of these complex enzymes is necessary.

Besides the work on NR-PKS there has also been a lot of work on highly reducing PKS (HR-PKS) in filamentous fungi. These PKSs are also of interest because they come in different modes of reduction leading to a wide range of chemical diversity. Early studies also focused on the understanding of these complex enzymes and especially on the PKS responsible for the statin, lovastatin ([@B34]), the mycotoxin fumonisin ([@B70], [@B71]) and the protein transport inhibitor brefeldin ([@B68]). The brefeldin study also demonstrated the need to consider the different tailoring enzymes necessary for the final product and specific product release. The PKS only creates the core structure, while different tailoring enzymes make additional modifications. This also represents a potential for the manipulation of different tailoring enzymes, such as cytochrome P450s ([@B43]) or others, that may appear more frequently in the future. There have also been some success stories concerning the swapping of domains and in turn the discovery of novel products. Two recent studies one with an NR-PKS, with asperfuranone biosynthesis ([@B31]), and the other an HR-PKS-NRPS hybrid, from tenellin and desmethylbassianin ([@B15]) successfully made domain swaps with the HR-PKS portion, which resulted in "unnatural" NPs. Additionally, other studies have focused on PKS-NRPS hybrids in order to understand how these different components communicate ([@B64]). In one study, [@B27] utilized 57 different combinations with 34 different module switches of various fungal PKS-NRPS hybrids to yield six novel compounds. In filamentous fungi, only few studies have yet been devoted to NRPS engineering. Prior studies are mostly seen in bacteria ([@B5]), but the potential in fungi is still there for further discovery. The engineering of fungal biosynthetic enzymes such as PKS or NRPS present a platform for the discovery of novel chemical derivatives that could hold the potential for new bioactive compounds (Figure [1C](#F1){ref-type="fig"}). With continuing work on the understanding of this complex biosynthetic machinery, hopefully one day we can successfully design novel combinations to get products of desired complexity.

Perspectives
============

Synthetic biology for the discovery and understanding of fungal NPs is an ever-evolving field. With the advancement of the different techniques presented herein the possibilities are endless for the production of novel/bioactive NPs. Additionally, with the rapid discovery in different genome editing and genetic manipulation tools such as the bacterial derived CRISPR-Cas9 system ([@B14]), these could also be applied to filamentous fungi to further expand the toolbox for the next new NPs. Moreover, other efforts must be done in order to create an organism with a minimal genome. This would mean for an organism to display reduced genome complexity and be engineered to have all the necessary production chassis for NP production. Filamentous fungi harness the capacity to produce a multitude of different NPs, they just need to be discovered. The future is very bright and since there is a need for novel bioactive compounds, because of the ever-present antibiotic resistance problem that is being seen, these particular platforms are of utmost importance.
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